ASH 2021: What to Know About This Year's Conference
The 63rd American Society of Hematology (ASH) Annual Meeting and Exposition is back to meeting in person! This year, it will be held December 11-14, 2021, at the Georgia World Congress Center in Atlanta.
Read More >
Mutations in Blood Cancers Associated with Lower Odds of Alzheimer's Disease
Random changes in certain genes that cause blood-forming stem cells to accumulate unchecked, and that have been shown to increase tenfold the risk of developing a blood cancer, may be associated with a reduced risk of Alzheimer's disease.
Read More >
Phase II CAPTIVATE Study: Ibrutinib + Venetoclax Results in First-Line CLL
According to results of the Phase II CAPTIVATE trial (NCT02910583) presented at the 2021 American Society of Hematology Annual Meeting, the use of ibrutinib plus venetoclax in the first-line setting for patients with previously untreated chronic lymphocytic leukemia (CLL) continued to result in responses that were deep and durable (Abstract 68).
Read More >
Updated Data from the Phase I/II BRUIN Clinical Trial for Pirtobrutinib
Updated clinical data from the global Phase I/II BRUIN clinical trial of pirtobrutinib in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) was presented in oral presentations at the 2021 American Society of Hematology (ASH) Annual Meeting (Abstracts 391 and 381).
Acalabrutinib & Rituximab Treatment for Previously Untreated CLL/SLL
High-frequency, low-dose rituximab in combination with acalabrutinib is a well-tolerated, effective therapy for patients with previously untreated chronic lymphocytic leukemia (CLL) that could be the basis for regimens incorporating other novel agents, according to findings recently presented at 2021 American Society of Hematology Annual Meeting & Exposition (Abstract 2640).
Exploring the Addition of Ublituximab & Umbralisib to Ibrutinib for CLL
Recent research demonstrated that the novel combination of a BTK inhibitor, PI3K inhibitor, and anti-CD20 monoclonal antibody was well-tolerated and effective for chronic lymphocytic leukemia (CLL), with 77 percent of evaluable patients achieving undetectable MRD.
Outcomes Among CLL Patients After Covalent BTK Inhibitor & Venetoclax Exposure
A recent study exploring the treatment outcomes among chronic lymphocytic leukemia (CLL) patients who had previous exposure to both a covalent Bruton's tyrosine kinase (BTK) inhibitor and venetoclax highlight the current unmet need for effective therapies for this patient population. These findings were recently presented at the 2021 American Society of Hematology Annual Meeting & Exposition (Abstract 2628).
Drug Combination Keeps CLL in Young Patients in Remission for Years
Young patients with chronic lymphocytic leukemia (CLL) can enjoy long remissions on the drug ibrutinib, but must stay on it indefinitely to keep the cancer in remission.
Patient Outcomes Following Non-Covalent BTK Inhibitor Discontinuation
A study recently presented at the 2021 American Society of Hematology Annual Meeting & Exposition offered insights into the outcomes of patients with chronic lymphocytic leukemia (CLL) and Richter transformation following the discontinuation of a non-covalent Bruton's tyrosine kinase (BTK) inhibitor (Abstract 2629).
A Connection Between BCR Signaling & NAMPT in Richter's Syndrome
One management challenge still facing many hem/oncs specializing in chronic lymphocytic leukemia is Richter's syndrome (RS), a rare complication characterized by the sudden transformation of the CLL/SLL into a significantly more aggressive form of large cell lymphoma.
Read More >
Targeted Agents for CLL Patients Aged 80 Years & Older
Researchers conducted a pooled analysis of patients 80 years or older in six Phase II and III studies in the frontline setting to clarify outcomes of targeted treatments regarding relevant clinical endpoints, including overall survival and causes of death.
Study Confirms COVID-19 Severe Outcomes in Patients with Lymphoid Malignancy
the pandemic, it has been well established that cancer patients have a 1.7-fold
increased risk of contracting SARS-CoV-2 and higher rates of severe events and
mortality compared with general population.
Fixed-Duration Ibrutinib + Venetoclax for Elderly or Unfit CLL Patients
The oral combination of ibrutinib plus
venetoclax—administered once-daily in a fixed-duration—demonstrated superior
undetectable MRD responses in elderly or unfit patients with previously
untreated chronic lymphocytic leukemia (CLL) when compared to chlorambucil plus
obinutuzumab, according to the first prospective data from the GLOW study.
Read More >